NASDAQ:GYRE Gyre Therapeutics (GYRE) Stock Price, News & Analysis → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free GYRE Stock Alerts $10.88 +0.18 (+1.68%) (As of 05:21 PM ET) Add Compare Share Share Today's Range$10.62▼$11.2250-Day Range$9.95▼$17.5352-Week Range$3.31▼$30.40Volume58,875 shsAverage Volume78,867 shsMarket Capitalization$930.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Gyre Therapeutics alerts: Email Address Gyre Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.38Based on 6 Articles This WeekInsider TradingSelling Shares$282,600 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.45) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.34 out of 5 starsMedical Sector895th out of 927 stocksPharmaceutical Preparations Industry428th out of 439 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Gyre Therapeutics.Read more about Gyre Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.79% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gyre Therapeutics has recently increased by 122.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGyre Therapeutics does not currently pay a dividend.Dividend GrowthGyre Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GYRE. Previous Next 3.0 News and Social Media Coverage News SentimentGyre Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Gyre Therapeutics this week, compared to 1 article on an average week.Search Interest3 people have searched for GYRE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows1 people have added Gyre Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $282,600.00 in company stock.Percentage Held by InsidersOnly 2.92% of the stock of Gyre Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 23.99% of the stock of Gyre Therapeutics is held by institutions.Read more about Gyre Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Gyre Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.30) per share.Price to Book Value per Share RatioGyre Therapeutics has a P/B Ratio of 60.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gyre Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe only AI company to buyMusk originally co-founded OpenAI with Sam Altman back in 2015. But after a series of disagreements, Musk left the company in 2018. And while Musk and Altman continue to fight it out for the future of artificial intelligence, including a bitter lawsuit… There is one key area they both agree on – a critical technology I call “The AI Keystone.”You must read this new presentation from Porter Stansberry. About Gyre Therapeutics Stock (NASDAQ:GYRE)Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Read More GYRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GYRE Stock News HeadlinesMay 4, 2024 | insidertrades.comNassim Usman Sells 20,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) StockJune 1 at 6:46 AM | americanbankingnews.comGyre Therapeutics (NASDAQ:GYRE) Stock Price Up 5.1%May 31, 2024 | americanbankingnews.comGyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.15May 30, 2024 | globenewswire.comGyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial HypertensionMay 29, 2024 | americanbankingnews.comGyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 122.9% in MayMay 28, 2024 | globenewswire.comGyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® IndexesMay 26, 2024 | americanbankingnews.comGyre Therapeutics (NASDAQ:GYRE) Shares Down 7.2% May 12, 2024 | seekingalpha.comGyre Therapeutics GAAP EPS of $0.03, revenue of $27.17MMay 11, 2024 | finance.yahoo.comGyre Therapeutics Reports First Quarter 2024 EarningsMay 10, 2024 | finanznachrichten.deGyre Therapeutics, Inc.: Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | msn.comGYRE Stock Earnings: Gyre Therapeutics Reported Results for Q1 2024May 9, 2024 | globenewswire.comGyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 27, 2024 | finance.yahoo.comPublic companies are Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) biggest owners and were rewarded after market cap rose by US$137m last weekApril 13, 2024 | seekingalpha.comGyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In TimeApril 5, 2024 | investing.comGyre therapeutics director Nassim Usman sells shares worth $323,000March 26, 2024 | markets.businessinsider.comGyre Therapeutics Posts Loss In 2023March 26, 2024 | globenewswire.comGyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 26, 2024 | seekingalpha.comRNAZ TransCode Therapeutics, Inc.March 21, 2024 | globenewswire.comGyre Therapeutics Expands Board of Directors with Appointment of Rodney L. NussbaumMarch 12, 2024 | finance.yahoo.comGyre Therapeutics, Inc. (GYRE) stock forecast and price targetFebruary 28, 2024 | seekingalpha.comTVTX Travere Therapeutics, Inc.February 22, 2024 | msn.comCantor Fitzgerald Downgrades RAPT Therapeutics (RAPT)December 21, 2023 | morningstar.comGyre Therapeutics IncDecember 15, 2023 | marketwatch.comGyre Therapeutics Names Han Ying As CEODecember 15, 2023 | finance.yahoo.comTotus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B FundingSee More Headlines Receive GYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/04/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GYRE Previous SymbolNASDAQ:GYRE CUSIPN/A CIK1124105 Webwww.catalystbiosciences.com Phone(619) 949-3681Fax336-480-2107Employees593Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,930,000.00 Net MarginsN/A Pretax Margin-61.16% Return on Equity-730.65% Return on Assets-124.94% Debt Debt-to-Equity RatioN/A Current Ratio3.22 Quick Ratio2.97 Sales & Book Value Annual Sales$113.45 million Price / Sales8.06 Cash Flow$0.23 per share Price / Cash Flow45.67 Book Value$0.18 per share Price / Book59.44Miscellaneous Outstanding Shares85,510,000Free Float83,013,000Market Cap$914.96 million OptionableNo Data Beta2.05 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Han Ying Ph.D.CEO & DirectorMr. Songjiang MaPresident & DirectorMs. Ruoyu Chen (Age 54)Interim Chief Financial Officer Mr. Weiguo YeChief Operating OfficerMs. Seline E. Miller CPA (Age 55)Senior Vice President of Finance Key CompetitorsCorcept TherapeuticsNASDAQ:CORTHUTCHMEDNASDAQ:HCMUltragenyx PharmaceuticalNASDAQ:RAREMerusNASDAQ:MRUSPrestige Consumer HealthcareNYSE:PBHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 2,999 shares on 5/10/2024Ownership: 0.228%Nassim UsmanSold 20,000 sharesTotal: $282,600.00 ($14.13/share)View All Insider TransactionsView All Institutional Transactions GYRE Stock Analysis - Frequently Asked Questions How have GYRE shares performed in 2024? Gyre Therapeutics' stock was trading at $25.69 on January 1st, 2024. Since then, GYRE shares have decreased by 57.6% and is now trading at $10.88. View the best growth stocks for 2024 here. Are investors shorting Gyre Therapeutics? Gyre Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 169,600 shares, an increase of 122.9% from the April 30th total of 76,100 shares. Based on an average daily volume of 68,700 shares, the days-to-cover ratio is presently 2.5 days. Currently, 0.8% of the company's stock are short sold. View Gyre Therapeutics' Short Interest. When is Gyre Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our GYRE earnings forecast. How were Gyre Therapeutics' earnings last quarter? Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted its quarterly earnings data on Thursday, May, 9th. The company reported $0.04 earnings per share (EPS) for the quarter. The company had revenue of $27.17 million for the quarter. Who are Gyre Therapeutics' major shareholders? Gyre Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.23%). View institutional ownership trends. How do I buy shares of Gyre Therapeutics? Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GYRE) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersNext President (Not Trump. Not Biden.)The Freeport SocietyWas the Great Financial Crisis fun?Brooks EnterprisesCollapse of the Petrodollar Colonial MetalsAI's Next Magnificent SevenThe Oxford Club[Webinar] Understanding Covered CallsOICWhat’s Pelosi Buying Now?Altimetry[Urgent!] Generational Wealth GameplanCrypto 101 MediaAre You Positioned For The New Energy Goldrush?Wealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
